GLP-1 receptor agonist
A class of pharmaceutical drugs that activate GLP-1 receptors, molecules that bind to and activate cell surface receptors called GLP-1 receptors, inducing metabolic, anti-inflammatory, and appetite-suppressing effects
As defined in GLP-1 Aren’t Just Weight Loss Drugs: A Provocative Discovery
Where it comes up · 3
- GLP-1 Aren’t Just Weight Loss Drugs: A Provocative Discovery15 claims
- Ozempic & Mounjaro: Same Shot. Opposite Results.4 claims
- Dr Ben Bikman - The Truth about GLP 1, Ozempic and Insulin resistance - Inspiring better health Ep.41 claim
Most important claims · 10 of 20Search all claims for “GLP-1 receptor agonist” →
- When GLP-1 receptors were deleted exclusively from the brain of mice, GLP-1 receptor agonists could no longer reduce inflammation, establishing that brain GLP-1 receptors are essential and sufficient for systemic anti-inflammatory effects.GLP-1 Aren’t Just Weight Loss Drugs: A Provocative Discovery
- GLP-1 receptor agonists extend and amplify a signal the body already uses, but when you amplify a signal that touches multiple organ systems, you don't just change appetite—you change traffic patterns across the whole physiology, including where fuel goes, how quickly it moves through the gut, how the pancreas responds to glucose, how the brain experiences reward, and how inflammatory signaling behaves.Ozempic & Mounjaro: Same Shot. Opposite Results.
- GLP-1 receptor agonists (weight loss drugs like semaglutide/Ozempic at standard dosing) function primarily by paralyzing the intestine through severe gastric slowing, keeping food in the stomach for over 24 hours, producing a sensation of constant nausea that patients describe as 'food noise going away,' and this paralysis can become permanent, leaving some patients with colostomy bags or requiring permanent nutritional infusion.Dr Ben Bikman - The Truth about GLP 1, Ozempic and Insulin resistance - Inspiring better health Ep.4
- GLP-1 receptor agonists can slow how fast food leaves the stomach, especially early in treatment; this slowing is not accidental but part of why people feel full faster and longer, and also why nausea happens, worsening reflux occurs, and constipation can become a real issue, particularly in people with baseline motility vulnerability.Ozempic & Mounjaro: Same Shot. Opposite Results.
- The FDA's preliminary evaluation as of January 13, 2026, had not found evidence that GLP-1 receptor agonists cause suicidal thoughts or actions, and the FDA requested removal of the suicidal behavior and ideation warning from GLP-1 receptor agonist medications used for weight management, stating their evaluation didn't identify an increased risk.Ozempic & Mounjaro: Same Shot. Opposite Results.
- GLP-1 receptor agonists may not be primarily weight loss drugs but rather multi-system therapeutic agents with effects beyond weight reduction.GLP-1 Aren’t Just Weight Loss Drugs: A Provocative Discovery
- When GLP-1 receptors were deleted specifically from the brain of mice, GLP-1 receptor agonists could not reduce inflammation, demonstrating that brain GLP-1 receptors are essential and sufficient for mediating systemic anti-inflammatory effects.GLP-1 Aren’t Just Weight Loss Drugs: A Provocative Discovery
- When GLP-1 receptors were deleted from blood cells and endothelial cells in mice, GLP-1 receptor agonists could still reduce inflammation, indicating that GLP-1 receptors in these peripheral tissues are not essential for the anti-inflammatory effect.GLP-1 Aren’t Just Weight Loss Drugs: A Provocative Discovery
- GLP-1 receptor agonists in humans almost certainly have benefits extending beyond weight loss, and these benefits may be partly attributable to reduced whole-body inflammation via brain-mediated mechanisms.GLP-1 Aren’t Just Weight Loss Drugs: A Provocative Discovery
- Guidance on GLP-1 medications and surgery has evolved; multi-society clinical practice guidance update states that most patients can continue GLP-1 receptor agonists before elective surgery with individualized risk assessment focused on delayed gastric emptying and aspiration risk.Ozempic & Mounjaro: Same Shot. Opposite Results.